drugset / Trial / NCT00171067
VALERIA: Valsartan in Combination With Lisinopril in Hypertensive Patients With Microalbuminuria
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to compare if the combination of valsartan 320 mg/lisinopril 20 mg versus the monotherapies of lisinopril 40 mg or valsartan 320 mg will result in a greater decrease of urinary albumin excretion measured as urinary albumin/creatinine ratio (UACR) in the first morning urine of hypertensive subjects with previously diagnosed microalbuminuria (MAU).
Timeline
- Start
- 2004-07
- Primary completion
- 2007-05
- Completion
- 2007-05
Publications
- Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
- Menne J, Farsang C, Deak L, Klebs S, Meier M, Handrock R, Sieder C, Haller H. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens. 2008 Sep;26(9):1860-7. doi: 10.1097/HJH.0b013e32830508aa.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LISINOPRIL ANHYDROUS | Small molecule | 20 mg | — |
| Subject | LISINOPRIL ANHYDROUS | Small molecule | 40 mg | — |
| Subject | Valsartan | Small molecule | 320 mg | — |